BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...EDBI, and new investors, Forth Management, Pilot House, Alex Denner’s Sarissa Capital, Shanda Group and QUAD...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Casdin Capital, the Cystic Fibrosis Foundation, Longevity Vision Fund, MiraeAsset Financial Group, Octagon Investments and QUAD...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Long-term data help two drugs sway ICER in drug price report

...data from randomized controlled trials to ICER that showed that Genvoya was superior to Stribild elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate...
BioCentury | Sep 23, 2019
Financial News

Sept. 23 Financial Quick Takes: Innate looks to add U.S. listing; plus Curamir's launch, Qihan Bio and Vedanta

...of its series C round, bringing the total amount raised $62.1 million. New investors including QUAD...
BioCentury | Aug 21, 2019
Financial News

Oncorus raises $79.5M series B with eye on global development

...new investors Surveyor Capital, Sphera Funds and five Korean firms: Shinhan Investment-Private Equity, UTC Investment, QUAD...
BioCentury | Jul 10, 2019
Clinical News

July 10 Clinical Quick Takes: Darzalex quad combo raises MM complete response, plus Geneos and ViiV

Adding Darzalex improves MM complete response rate in Phase II Genmab A/S (CSE:GEN; Pink:GMXAY) said Darzalex daratumumab in combination with Revlimid lenalidomide, Velcade bortezomib and dexamethasone met the primary endpoint in the Phase II GRIFFIN...
BioCentury | Apr 1, 2019
Clinical News

Apexigen's CD40 agonist shows response in pancreatic cancer

...Apexigen Inc. (San Carlos, Calif.) plus standard of care gemcitabine and Abraxane nab-paclitaxel or a quad...
...also included Opdivo. The responses included 11 confirmed partial responses and 2 unconfirmed PRs. The quad...
...trial, which will test the higher dose of APX005M as part of a triplet and quad...
BioCentury | Nov 7, 2018
Emerging Company Profile

ABL bispecifics

...Investment & Securities, Korea Investment Partners, New Flight, NS Investment, Paratus Investment, PTR Asset Management, Quad...
BioCentury | Jun 15, 2018
Financial News

ABL snags $65M in series C

...a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad...
BioCentury | Jun 8, 2018
Financial News

ABL snags $65M in series C

...a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad...
Items per page:
1 - 10 of 158